Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023

LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
September 29, 2022 17:00 ET | Source: Imunon, Inc.

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
September 15, 2022 08:30 ET | Source: Celsion Corporation

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE)...
July 19, 2022 08:30 ET | Source: Celsion Corporation

Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on...
April 08, 2022 16:30 ET | Source: Celsion Corporation

Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct...
November 15, 2021 08:30 ET | Source: Celsion CORP

Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update

Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE...
November 09, 2021 09:00 ET | Source: Celsion CORP

Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021

LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
November 08, 2021 09:00 ET | Source: Celsion CORP

Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses

Application Approval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, Celsion has raised...
September 30, 2021 09:00 ET | Source: Celsion CORP

Celsion to Present at Three Investment Conferences in October

LAWRENCEVILLE, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
August 12, 2021 08:00 ET | Source: Celsion CORP

Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update

Strong Balance Sheet Supports Focus in Immuno-Oncology and on Next-Generation Vaccine InitiativeConference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 12,...

Next Page keyboard_arrow_right